Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yunxiang Zhou
Institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
Observed institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
ORCID:
0000-0003-1000-0330
Observed ORCID:
0000-0003-1000-0330
OpenAlex ID:
A5102221085
Clinical significance of lipid pathway-targeted therapy in breast cancer
2025
·
Dan Li
, Pengcheng Jin
, et al.
·
Frontiers in Pharmacology
·
5
PDF
Management of malignant breast phyllodes tumor with rib invasion during pregnancy: a rare case report and literature review
2026
·
Sijie Yu
, Panni Li
, et al.
·
Frontiers in Oncology
·
1
PDF
Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
2025
·
Pengcheng Jin
, Xiawei Li
, et al.
·
Clinical and Experimental Obstetrics & Gynecology
·
1
PDF
Correction: Clinical efficacy of different methods for treatment of granulomatous lobular mastitis: A systematic review and network meta-analysis
2025
·
Yunxiang Zhou
, Leilai Xu
·
PLoS ONE
·
1
PDF
Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study.
2024
·
Yunxiang Zhou
, Zhiyun Zhang
, et al.
·
Journal of Clinical Oncology
·
1
Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer.
2024
·
Yunxiang Zhou
, Zhiyun Zhang
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Biomarkers of neoadjuvant dalpiciclib in patients with operable HER2-negative luminal B breast cancer in the DANCER trial.
2025
·
Yunxiang Zhou
, Zhiyun Zhang
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
7
Citation count:
10
H-index:
1
I10-index:
Year
Topic
Type